Consensus McKesson Corporation

Stocks

MCK

US58155Q1031

Pharmaceuticals

Market Closed - NYSE 16:00:02 2026-09-18 EDT			5-day change	1st Jan Change
874.65 ^USD	-0.56%		-0.78%	+6.63%

09-14	McKesson Continues to Face Medium-Term Headwinds From Declining Employer Coverage of GLP-1, RBC Says	MT
09-14	McKesson Corporation Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:45 AM

Evolution of the Average Target: McKesson Corporation

Evolution of the Target Price: McKesson Corporation

Changes in Analyst Recommendations: McKesson Corporation

d2.gdO33qajl1d-g9SRVaQgN-joYGgtGS7Fw3soh3MgT5s.wLyDncD3rwM_0qDBOZNUYrLfAjJ5UkSNmRF41DlWBdDli_Pn_PnYMBD3sw~a892269ed974656bb624334a70b448cc

Analysts' recommendations: McKesson Corporation

09-14	McKesson Continues to Face Medium-Term Headwinds From Declining Employer Coverage of GLP-1, RBC Says	MT
09-03	Argus Adjusts Price Target on McKesson to $970 From $850, Maintains Buy Rating	MT
08-19	McKesson's Specialty Drug Mix Helps Cushion Pricing Pressure, RBC Says	MT
08-19	RBC Initiates McKesson at Sector Perform With $845 Price Target	MT
08-18	Barclays Raises Price Target on McKesson to $1,000 From $925, Maintains Overweight Rating	MT
08-11	Wells Fargo Adjusts Price Target on McKesson to $933 From $812, Maintains Equalweight Rating	MT
08-06	Mizuho Adjusts Price Target on McKesson to $905 From $885	MT
08-06	TD Cowen Adjusts Price Target on McKesson to $1,006 From $989	MT
08-06	Evercore ISI Adjusts Price Target on McKesson to $1,000 From $860	MT
08-06	Baird Adjusts Price Target on McKesson to $1,015 From $955	MT
08-06	UBS Adjusts Price Target on McKesson to $1,080 From $1,050, Maintains Buy Rating	MT
08-06	BofA Securities Adjusts Price Target on McKesson to $1,050 From $950	MT
07-23	Citigroup Raises McKesson Price Target to $1,000 From $945, Maintains Buy Rating	MT
07-22	Baird Adjusts Price Target on McKesson to $955 From $941, Maintains Outperform Rating	MT
07-21	TD Cowen Adjusts McKesson Price Target to $989 From $1,012, Maintains Buy Rating	MT
07-21	BofA Securities Adjusts McKesson Price Target to $925 From $900	MT
07-14	Leerink Partners Adjusts Price Target on McKesson to $950 From $970, Maintains Outperform Rating	MT
07-07	Evercore ISI Adjusts Price Target on McKesson to $860 From $850	MT
06-10	Barclays Cuts McKesson Price Target to $925 From $1,050, Maintains Overweight Rating	MT
06-05	Argus Adjusts Price Target on McKesson to $850 From $1,050, Maintains Buy Rating	MT
05-14	Citigroup Adjusts Price Target on McKesson to $945 From $975, Maintains Buy Rating	MT
05-12	Wells Fargo Adjusts Price Target on McKesson to $812 From $925, Maintains Equalweight Rating	MT
05-08	McKesson's Fiscal 2027 Guidance 'Encouraging,' Cencora Selloff Overdone, Morgan Stanley Says	MT
05-08	UBS Adjusts McKesson Price Target to $1,050 From $1,000, Maintains Buy Rating	MT
05-08	Deutsche Bank Adjusts McKesson Price Target to $875 From $973, Maintains Buy Rating	MT

More recommendations

Pharmaceuticals Wholesale

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
MCKESSON CORPORATION		+12.13%
CARDINAL HEALTH, INC.		+20.21%
SIGMA HEALTHCARE LIMITED		+25.42%
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD		+30.8%
HUADONG MEDICINE CO., LTD		+59.36%
H. LUNDBECK A/S		+14.14%
SINOPHARM GROUP CO. LTD.		+40.62%
GALENICA AG	-	+7.35%
MEDIPAL HOLDINGS CORPORATION		+8.21%
JOINTOWN PHARMACEUTICAL GROUP CO., LTD		+13.7%
Average		+23.19%
Weighted average by Cap.		+18.28%